Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Research opens door to new prostate cancer treatment

Research opens door to new prostate cancer treatment

Researchers from the Centenary Institute’s Origins of Cancer Program have discovered new links between nutrition and prostate cancer. [More]
Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor. [More]
Cancer Research UK, EPSRC partner to fund multidisciplinary cancer research projects

Cancer Research UK, EPSRC partner to fund multidisciplinary cancer research projects

Cancer Research UK has partnered with the Engineering and Physical Sciences Research Council, to co-fund multidisciplinary research projects. [More]
TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA. [More]
Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Myriad announces Prolaris® test biopsy results from EMPATHY-P study at European Association of Urology annual meeting

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. [More]
New report highlights the need for disclosing Alzheimer's diagnosis to patients

New report highlights the need for disclosing Alzheimer's diagnosis to patients

The Alzheimer's Association's 2015 Alzheimer's Disease Facts and Figures report, released today, found that only 45 percent of people with Alzheimer's disease or their caregivers say they were told the diagnosis by their doctor. [More]
Implementation of video-based decision aids influences care decisions in urology

Implementation of video-based decision aids influences care decisions in urology

After Group Health Cooperative implemented video-based decision aids for men with two common prostate conditions, rates of elective surgery for benign prostatic hyperplasia (BPH) and rates of active treatment for localized prostate cancer declined over six months. [More]
Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment as long as possible after the removal of the prostate in order to prevent unwanted side effects. [More]
Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T. [More]
MED15 may serve as prognostic marker for HNSCC recurrence

MED15 may serve as prognostic marker for HNSCC recurrence

A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology. [More]
Janssen announces acquisition of XO1

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. [More]
Researchers reveal how omega-3 fatty acids inhibit growth of prostate cancer cells

Researchers reveal how omega-3 fatty acids inhibit growth of prostate cancer cells

Washington State University researchers have found a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings, which are at odds with a 2013 study asserting that omega-3s increase the risk of prostate cancer, point the way to more effective anti-cancer drugs. [More]
NCCN panelists discuss on evidence-based decision-making at bedside

NCCN panelists discuss on evidence-based decision-making at bedside

On Friday, March 13, 2015, as part of its 20th Annual Conference: Advancing the Standard of Cancer Care, the National Comprehensive Cancer Network hosted its second roundtable, Value-Based Decision-Making at the Bedside, which reflected on the tools available to oncology clinicians, such as clinical practice guidelines and pathways, and how the use of these tools has impacted bedside evidence-based decision-making for both physicians and patients, the criteria used to assess shared decision-making, and the relationship between outcomes and cost when determining value. [More]
Study may help men make better decisions about aggressive prostate cancer treatments

Study may help men make better decisions about aggressive prostate cancer treatments

A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments. [More]
Study defines new subtype of 'lethal' prostate cancer

Study defines new subtype of 'lethal' prostate cancer

A University of Colorado Cancer Center study published in the journal Cancer Research defines a new, distinct subtype of "lethal" prostate cancer marked by the loss of two genes, MAP3K7 and CHD1. Overall about 10 percent of men with prostate cancer will die from the disease. [More]
Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. [More]
ERC project aims to identify new treatments for prostate cancer

ERC project aims to identify new treatments for prostate cancer

The European Research Council (ERC) has awarded a Consolidator Grant to ICREA researcher Xavier Salvatella, head of the Molecular Biophysics Lab at the Institute for Research in Biomedicine (IRB Barcelona). [More]
AdMeTech Foundation announces launch of statewide prostate cancer awareness program

AdMeTech Foundation announces launch of statewide prostate cancer awareness program

AdMeTech Foundation today announced the launch of a statewide prostate cancer education and awareness campaign supported by the Massachusetts Department of Public Health. [More]
Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a life-threatening lung condition that affects approximately 200,000 people a year in the United States and has a higher mortality rate than breast and prostate cancer combined. The condition most often occurs in people who are critically ill or who have significant injuries; those who do survive it often experience profound skeletal muscle weakness. [More]
Researchers develop improved MRI technique to provide effective treatment for prostate cancer

Researchers develop improved MRI technique to provide effective treatment for prostate cancer

A research team including NIBIB-funded scientists has developed an improved MRI technique with the potential to provide more precise and effective treatment for prostate cancer. The imaging technique improves upon standard MRI to obtain clearer images of the extent of the tumor and its exact location. A sharper image can provide more accurate biopsies, enable better treatment planning, and help surgeons pinpoint the tumor while sparing surrounding healthy tissue. [More]
Advertisement
Advertisement